Ignite Creation Date:
2025-12-24 @ 1:57 PM
Ignite Modification Date:
2025-12-29 @ 11:09 PM
Study NCT ID:
NCT05911295
Status:
RECRUITING
Last Update Posted:
2025-12-15
First Post:
2023-06-09
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Sponsor:
Seagen, a wholly owned subsidiary of Pfizer
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-09-22
Start Date Type:
ACTUAL
Primary Completion Date:
2026-06-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-04-30
Completion Date Type:
ESTIMATED
First Submit Date:
2023-06-09
First Submit QC Date:
None
Study First Post Date:
2023-06-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-08
Last Update Post Date:
2025-12-15
Last Update Post Date Type:
ESTIMATED